BiotechTube

ASP2215

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AML

Conditions

AML

Trial Timeline

— → —

NCT ID
NCT03315299

About ASP2215

ASP2215 is a pre-clinical stage product being developed by Astellas Pharma for AML. The current trial status is completed. This product is registered under clinical trial identifier NCT03315299. Target conditions include AML.

What happened to similar drugs?

2 of 14 similar drugs in AML were approved

Approved (2) Terminated (1) Active (11)
✅Venetoclax + AzacitidineAbbVieApproved
✅Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe SubstratesRigel PharmaceuticalsApproved
🔄Quizartinib + Salvage ChemotherapyDaiichi SankyoPhase 3
🔄gilteritinib + LoDAC (Low Dose Cytarabine) + Azacitidine + MEC (Mitoxantrone, Etoposide, Cytarabine) + FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)Astellas PharmaPhase 3
🔄gilteritinib + azacitidineAstellas PharmaPhase 3
🔄Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + FludarabineAstellas PharmaPhase 3
🔄Venetoclax + Azacitidine + DecitabineAbbViePhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03315299Pre-clinicalCompleted
NCT02571816Phase 1Completed

Competing Products

20 competing products in AML

See all competitors
ProductCompanyStageHype Score
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
AC220Daiichi SankyoPhase 1
29
Quizartinib + Salvage ChemotherapyDaiichi SankyoPhase 3
40
QuizartinibDaiichi SankyoPhase 1
29
gilteritinibAstellas PharmaPre-clinical
26
gilteritinibAstellas PharmaPre-clinical
26
Gilteritinib + Venetoclax + AzacitidineAstellas PharmaPhase 1/2
36
Gilteritinib + PlaceboAstellas PharmaPhase 2
35
Venetoclax + GilteritinibAstellas PharmaPhase 1
29
GilteritinibAstellas PharmaPhase 1
29
Gilteritinib + Ivosidenib + EnasidenibAstellas PharmaPhase 1
36
gilteritinib + LoDAC (Low Dose Cytarabine) + Azacitidine + MEC (Mitoxantrone, Etoposide, Cytarabine) + FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)Astellas PharmaPhase 3
40
gilteritinib + atezolizumabAstellas PharmaPhase 1/2
32
Gilteritinib + Venetoclax + Azacitidine (AZA) + Local standard of care (SOC)Astellas PharmaPhase 2/3
45
gilteritinib + fludarabine + cytarabine + granulocyte colony-stimulating factor (G-CSF)Astellas PharmaPhase 1/2
24
ASP7517Astellas PharmaPhase 1/2
32
gilteritinib + azacitidineAstellas PharmaPhase 3
40
Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + FludarabineAstellas PharmaPhase 3
44
decitabine Induction Chemotherapy + Induction ChemotherapyEisaiPhase 2
27
Decitabine + DecitabineEisaiPhase 2
27